Neurotrophin signaling in cancer

Handbook of Neurotoxicity

Volumn 3, Issue , 2014, Pages 1825-1847

  Tan, Fei ^a   Thiele, Carol J ^b   Li, Zhijie ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84979645812     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5836-4_49     Document Type: Chapter

References (86)

1. Acheson, A., Conover, J. C., Fandl, J. P., DeChiara, T. M., Russell, M., Thadani, A., Squinto, S. P., Yancopoulos, G. D., & Lindsay, R. M. (1995). A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature, 374, 450-453.
2. Adriaenssens, E., Vanhecke, E., Saule, P., Mougel, A., Page, A., Romon, R., Nurcombe, V., Le Bourhis, X., & Hondermarck, H. (2008). Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Research, 68, 346-351.
3. Akil, H., Perraud, A., Melin, C., Jauberteau, M. O., & Mathonnet, M. (2011). Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell 1survival. PLoS One, 6, e25097.
4. Arevalo, J. C., & Wu, S. H. (2006). Neurotrophin signaling: Many exciting surprises! Cellular and Molecular Life Sciences, 63, 1523-1537.
5. Benedetti, M., Levi, A., & Chao, M. V. (1993). Differential expression of nerve growth factor receptors leads to altered binding affinity and neurotrophin responsiveness. Proceedings of the National Academy of Sciences of the United States of America, 90, 7859-7863.
6. Binder, D. K., & Scharfman, H. E. (2004). Brain-derived neurotrophic factor. Growth Factors, 22, 123-131.
7. Blasco-Gutierrez, M. J., Jose-Crespo, I. J., Zozaya-Alvarez, E., Ramos-Sanchez, R., & Garcia- Atares, N. (2007). TrkC: A new predictive marker in breast cancer? Cancer Investigation, 25, 405-410.
8. Bouzas-Rodriguez, J., Cabrera, J. R., Delloye-Bourgeois, C., Ichim, G., Delcros, J. G., Raquin, M. A., Rousseau, R., Combaret, V., Benard, J., Tauszig-Delamasure, S., et al. (2010). Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC- induced apoptosis. Journal of Clinical Investigation, 120, 850-858.
9. Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., Light, J. E., Kolla, V., & Evans, A. E. (2009). Trk receptor expression and inhibition in neuroblastomas. Clinical Cancer Research, 15, 3244-3250.
10. Brunetto de Farias, C., Rosemberg, D. B., Heinen, T. E., Koehler-Santos, P., Abujamra, A. L., Kapczinski, F., Brunetto, A. L., Ashton-Prolla, P., Meurer, L., Reis Bogo, M., et al. (2010). BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer. Oncology, 79, 430-439.
11. Butte, M. J. (2001). Neurotrophic factor structures reveal clues to evolution, binding, specificity, and receptor activation. Cellular and Molecular Life Sciences, 58, 1003-1013.
12. Camoratto, A. M., Jani, J. P., Angeles, T. S., Maroney, A. C., Sanders, C. Y., Murakata, C., Neff, N. T., Vaught, J. L., Isaacs, J. T., & Dionne, C. A. (1997). CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. International Journal of Cancer, 72, 673-679.
13. Chan, E., Mulkerin, D., Rothenberg, M., Holen, K. D., Lockhart, A. C., Thomas, J., & Berlin, J. (2008). A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Investigational New Drugs, 26, 241-247.
14. Chao, M. V., Bothwell, M. A., Ross, A. H., Koprowski, H., Lanahan, A. A., Buck, C. R., & Sehgal, A. (1986). Gene transfer and molecular cloning of the human NGF receptor. Science, 232, 518-521.
15. Clary, D. O., & Reichardt, L. F. (1994). An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. Proceedings of the National Academy of Sciences of the United States of America, 91, 11133-11137.
16. Davidson, B., Reich, R., Lazarovici, P., Ann Florenes, V., Nielsen, S., & Nesland, J. M. (2004). Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Research and Treatment, 83, 119-128.
17. Descamps, S., Toillon, R. A., Adriaenssens, E., Pawłowski, V., Cool, S. M., Nurcombe, V., Le Bourhis, X., Boilly, B., Peyrat, J. P., & Hondermarck, H. (2001). Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. Journal of Biological Chemistry, 276, 17864-17870.
18. Djakiew, D. (2000). Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate, 42, 150-160.
19. Eggert, A., Grotzer, M. A., Ikegaki, N., Liu, X. G., Evans, A. E., & Brodeur, G. M. (2002). Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Research, 62, 1802-1808.
20. Evans, A. E., Kisselbach, K. D., Yamashiro, D. J., Ikegaki, N., Camoratto, A. M., Dionne, C. A., & Brodeur, G. M. (1999). Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clinical Cancer Research, 5, 3594-3602.
21. Evans, A. E., Kisselbach, K. D., Liu, X., Eggert, A., Ikegaki, N., Camoratto, A. M., Dionne, C., & Brodeur, G. M. (2001). Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Medical and Pediatric Oncology, 36, 181-184.
22. Geiger, T. R., Song, J. Y., Rosado, A., & Peeper, D. S. (2011). Functional characterization of human cancer-derived TRKB mutations. PLoS One, 6, e16871.
23. George, D. J., Dionne, C. A., Jani, J., Angeles, T., Murakata, C., Lamb, J., & Isaacs, J. T. (1999). Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT- 5555). Cancer Research, 59, 2395-2401.
24. Gills, J. J., & Dennis, P. A. (2009). Perifosine: Update on a novel Akt inhibitor. Current Oncology Reports, 11, 102-110.
25. Gotz, R., Koster, R., Winkler, C., Raulf, F., Lottspeich, F., Schartl, M., & Thoenen, H. (1994). Neurotrophin-6 is a new member of the nerve growth factor family. Nature, 372, 266-269.
26. Harada, T., Yatabe, Y., Takeshita, M., Koga, T., Yano, T., Wang, Y., & Giaccone, G. (2011). Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clinical Cancer Research, 17, 2638-2645.
27. Harel, L., Costa, B., Tcherpakov, M., Zapatka, M., Oberthuer, A., Hansford, L. M., Vojvodic, M., Levy, Z., Chen, Z. Y., Lee, F. S., et al. (2009). CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron, 63, 585-591.
28. Hempstead, B. L., Martin-Zanca, D., Kaplan, D. R., Parada, L. F., & Chao, M. V. (1991). High- affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature, 350, 678-683.
29. Jaboin, J., Kim, C. J., Kaplan, D. R., & Thiele, C. J. (2002). Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Research, 62, 6756-6763.
30. Kaplan, D. R., & Miller, F. D. (2000). Neurotrophin signal transduction in the nervous system. Current Opinion in Neurobiology, 10, 381-391.
31. Karin, M., & Lin, A. (2002). NF-kappaB at the crossroads of life and death. Nature Immunology, 3, 221-227.
32. Klein, R., Parada, L. F., Coulier, F., & Barbacid, M. (1989). trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO Journal, 8, 3701-3709.
33. Klein, R., Nanduri, V., Jing, S. A., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991). The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell, 66, 395-403.
34. Koizumi, H., Morita, M., Mikami, S., Shibayama, E., & Uchikoshi, T. (1998). Immunohistochemical analysis of TrkA neurotrophin receptor expression in human non-neuronal carcinomas. Pathology International, 48, 93-101.
35. Krygier, S., & Djakiew, D. (2002). Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. International Journal of Cancer, 98, 1-7.
36. Lagadec, C., Meignan, S., Adriaenssens, E., Foveau, B., Vanhecke, E., Romon, R., Toillon, R. A., Oxombre, B., Hondermarck, H., & Le Bourhis, X. (2009). TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene, 28, 1960-1970.
37. Lamballe, F., Klein, R., & Barbacid, M. (1991). trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell, 66, 967-979.
38. Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001). Regulation of cell survival by secreted proneurotrophins. Science, 294, 1945-1948.
39. Li, Z., Jaboin, J., Dennis, P. A., & Thiele, C. J. (2005). Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Research, 65, 2070-2075.
40. Li, Z., Tan, F., & Thiele, C. J. (2007a). Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells. Molecular Cancer Therapeutics, 6, 3113-3121.
41. Li, Z., Zhang, J., Liu, Z., Woo, C. W., & Thiele, C. J. (2007b). Downregulation of Bim by brain- derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death and Differentiation, 14, 318-326.
42. Li, Z., Oh, D. Y., Nakamura, K., & Thiele, C. J. (2011). Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer, 117, 5412-5422.
43. Lucarelli, E., Kaplan, D., & Thiele, C. J. (1997). Activation of trk-A but not trk-B signal transduction pathway inhibits growth of neuroblastoma cells. European Journal of Cancer, 33, 2068-2070.
44. MacGrogan, D., Saint-Andre, J. P., & Dicou, E. (1992). Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. Journal of Neurochemistry, 59, 1381-1391.
45. Mahadeo, D., Kaplan, L., Chao, M. V., & Hempstead, B. L. (1994). High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors. J Biol Chem, 269, 6884-6891.
46. Marshall, J. L., Kindler, H., Deeken, J., Bhargava, P., Vogelzang, N. J., Rizvi, N., Luhtala, T., Boylan, S., Dordal, M., Robertson, P., et al. (2005). Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Investigational New Drugs, 23, 31-37.
47. Miknyoczki, S. J., Dionne, C. A., Klein-Szanto, A. J., & Ruggeri, B. A. (1999). The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Annals of the New York Academy of Sciences, 880, 252-262.
48. Minturn, J. E., Evans, A. E., Villablanca, J. G., Yanik, G. A., Park, J. R., Shusterman, S., Groshen, S., Hellriegel, E. T., Bensen-Kennedy, D., Matthay, K. K., et al. (2011). Phase I trial of lestaurtinib for children with refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study. Cancer Chemotherapy and Pharmacology, 68, 1057-1065.
49. Muragaki, Y., Chou, T. T., Kaplan, D. R., Trojanowski, J. Q., & Lee, V. M. (1997). Nerve growth factor induces apoptosis in human medulloblastoma cell lines that express TrkA receptors. Journal of Neuroscience, 17, 530-542.
50. Nakagawara, A. (1998a). Molecular basis of spontaneous regression of neuroblastoma: Role of neurotrophic signals and genetic abnormalities. Human Cell, 11, 115-124.
51. Nakagawara, A. (1998b). TheNGF story and neuroblastoma. Medical and Pediatric Oncology, 31, 113-115.
52. Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., & Brodeur, G. M. (1993). Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. New England Journal of Medicine, 328, 847-854.
53. Nakagawara, A., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1994). Expression and function of TRK-B and BDNF in human neuroblastomas. Molecular Cell Biology, 14, 759-767.
54. Nakamura, K., Martin, K. C., Jackson, J. K., Beppu, K., Woo, C. W., & Thiele, C. J. (2006). Brain- derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Research, 66, 4249-4255.
55. Nakamura, K., Tan, F., Li, Z., & Thiele, C. J. (2011). NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-lalpha. Molecular and Cellular Neuroscience, 46, 498-506.
56. Nikoletopoulou, V., Lickert, H., Frade, J. M., Rencurel, C., Giallonardo, P., Zhang, L., Bibel, M., & Barde, Y. A. (2010). Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature, 467, 59-63.
57. Nilsson, A. S., Fainzilber, M., Falck, P., & Ibanez, C. F. (1998). Neurotrophin-7: A novel member of the neurotrophin family from the zebrafish. FEBS Letters, 424, 285-290.
58. Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T. E., et al. (2004). Sortilin is essential for proNGF- induced neuronal cell death. Nature, 427, 843-848.
59. Pahl, H. L. (1999). Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, 6853-6866.
60. Patani, N., Jiang, W. G., & Mokbel, K. (2011). Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer. Cancer Cell International, 11, 23.
61. Radeke, M. J., Misko, T. P., Hsu, C., Herzenberg, L. A., & Shooter, E. M. (1987). Gene transfer and molecular cloning of the rat nerve growth factor receptor. Nature, 325, 593-597.
62. Reichardt, L. F. (2006). Neurotrophin-regulated signalling pathways. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 361, 1545-1564.
63. Ricci, A., Greco, S., Mariotta, S., Felici, L., Bronzetti, E., Cavazzana, A., Cardillo, G., Amenta, F., Bisetti, A., & Barbolini, G. (2001). Neurotrophins and neurotrophin receptors in human lung cancer. American Journal of Respiratory Cell and Molecular Biology, 25, 439-446.
64. Ryden, M., Sehgal, R., Dominici, C., Schilling, F. H., Ibanez, C. F., & Kogner, P. (1996). Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. British Journal of Cancer, 74, 773-779.
65. Scala, S., Wosikowski, K., Giannakakou, P., Valle, P., Biedler, J. L., Spengler, B. A., Lucarelli, E., Bates, S. E., & Thiele, C. J. (1996). Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Research, 56, 3737-3742.
66. Segal, R. A., Goumnerova, L. C., Kwon, Y. K., Stiles, C. D., & Pomeroy, S. L. (1994). Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proceedings of the National Academy of Sciences of the United States of America, 91, 12867-12871.
67. Snider, W. D. (1994). Functions of the neurotrophins during nervous system development: What the knockouts are teaching us. Cell, 77, 627-638.
68. Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001). Nerve growth factor signaling, neuroprotection, and neural repair. Annual Review of Neuroscience, 24, 1217-1281.
69. Straub, J. A., Sholler, G. L., & Nishi, R. (2007). Embryonic sympathoblasts transiently express TrkB in vivo and proliferate in response to brain-derived neurotrophic factor in vitro. BMC Developmental Biology, 7, 10.
70. Strohmaier, C., Carter, B. D., Urfer, R., Barde, Y. A., & Dechant, G. (1996). A splice variant of the neurotrophin receptor trkB with increased specificity for brain-derived neurotrophic factor. EMBO Journal, 15, 3332-3337.
71. Suzuki, T., Bogenmann, E., Shimada, H., Stram, D., & Seeger, R. C. (1993). Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. Journal of the National Cancer Institute, 85, 377-384.
72. Svensson, T., Ryden, M., Schilling, F. H., Dominici, C., Sehgal, R., Ibanez, C. F., & Kogner, P. (1997). Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma. European Journal of Cancer, 33, 2058-2063.
73. Tacconelli, A., Farina, A. R., Cappabianca, L., Desantis, G., Tessitore, A., Vetuschi, A., Sferra, R., Rucci, N., Argenti, B., Screpanti, I., et al. (2004). TrkA alternative splicing: A regulated tumor- promoting switch in human neuroblastoma. Cancer Cell, 6, 347-360.
74. Tauszig-Delamasure, S., Yu, L. Y., Cabrera, J. R., Bouzas-Rodriguez, J., Mermet-Bouvier, C., Guix, C., Bordeaux, M. C., Arumae, U., & Mehlen, P. (2007). The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm. Proceedings of the National Academy of Sciences of the United States of America, 104, 13361-13366.
75. Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., Kermani, P., Torkin, R., Chen, Z. Y., Lee, F. S., et al. (2005). ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. Journal of Neuroscience, 25, 5455-5463.
76. Thiele, C. J., Li, Z., & McKee, A. E. (2009). On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clinical Cancer Research, 15, 5962-5967.
77. Valenzuela, D. M., Maisonpierre, P. C., Glass, D. J., Rojas, E., Núñez, L., Kong, Y., Gies, D. R., Stitt, T. N., Ip, N. Y., & Yancopoulos, G. D. (1993). Alternative forms of rat TrkC with different functional capabilities. Neuron, 10, 963-974.
78. Vanhecke, E., Adriaenssens, E., Verbeke, S., Meignan, S., Germain, E., Berteaux, N., Nurcombe, V., Le Bourhis, X., & Hondermarck, H. (2011). Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clinical Cancer Research, 17, 1741-1752.
79. Wang, T., Lamb, M. L., Scott, D. A., Wang, H., Block, M. H., Lyne, P. D., Lee, J. W., Davies, A. M., Zhang, H. J., Zhu, Y., et al. (2008). Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases. Journal of Medicinal Chemistry, 51, 4672-4684.
80. Wiesmann, C., & de Vos, A. M. (2001). Nerve growth factor: Structure and function. Cellular and Molecular Life Sciences, 58, 748-759.
81. Yamashiro, D. J., Nakagawara, A., Ikegaki, N., Liu, X. G., & Brodeur, G. M. (1996). Expression of TrkC in favorable human neuroblastomas. Oncogene, 12, 37-41.
82. Yan, H., & Chao, M. V. (1991). Disruption of cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding. Journal of Biological Chemistry, 266, 12099-12104.
83. Yu, Y., Zhang, S., Wang, X., Yang, Z., & Ou, G. (2010). Overexpression of TrkB promotes the progression of colon cancer. APMIS, 118, 188-195.
84. Zage, P. E., Graham, T. C., Zeng, L., Fang, W., Pien, C., Thress, K., Omer, C., Brown, J. L., & Zweidler-McKay, P. A. (2011). The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer, 117, 1321-1391.
85. Zhang, S., Guo, D., Luo, W., Zhang, Q., Zhang, Y., Li, C., Lu, Y., Cui, Z., & Qiu, X. (2010). TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer, 10, 43.
86. Zupan, A. A., Osborne, P. A., Smith, C. E., Siegel, N. R., Leimgruber, R. M., & Johnson, E. M., Jr. (1989). Identification, purification, and characterization of truncated forms of the human nerve growth factor receptor. Journal of Biological Chemistry, 264, 11714-11720.